Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

6 Months Ended

Jun. 30, 2022

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of June 30, 2022 and December 31, 2021 were as follows:


	June 30, 2022		December 31, 2021
Accrued compensation expenses	$	26,087	$	508,343
Accrued research and development		304,052		229,090
Accrued professional fees		137,976		43,102
Other accounts payable and accrued expenses		5,764		63,374
Total	$	473,879	$	843,909